Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.

J Cancer Res Clin Oncol · 2020 · PMC7382655 · PMID 32385709

Europe PMC DOI

hedged sentence

0.4090

closest p · 8.2× alpha

0.4090

boldest claim

The sentences

showed a trendP = 0.409not close (p > 0.1)

Patients with an EGFR-dependent resistance mechanism more likely occurred in the base of exon 19del (53.3% in exon19del vs 17.6% in L858R, P = 0.017); while, alternative pathway activation showed a trend to present in the base of the L858R mutation (10.0% in exon19del vs 23.5% in L858R, P = 0.409).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.